Selumetinib Yields Modest Benefits in Rare Eye Cancer

The first randomized controlled trial of the MEK inhibitor selumetinib finds modest improvement in clinical outcomes of advanced uveal melanoma but high rates of adverse effects.
Medscape Medical News